News06/01/2026
NewLimit reports first preclinical candidate in 2025 review
NewLimit, Inc. →NewLimit reported selecting its first preclinical candidate during 2025 and developing its Ambrosia AI system for designing reprogramming payloads. The review described continued work across metabolic, immune and vascular programs.